ProQR Appoints ADAR Expert Dr. Peter A. Beal to Scientific Advisory Board to Focus on Axiomer® RNA A-to-I Editing Technology
10 avr. 2018 07h00 HE
|
ProQR Therapeutics N.V.
Key Updates Dr. Peter A. Beal joins ProQR’s scientific advisory board, bringing with him tremendous experience in the field of RNA-based therapeutics, particularly in the area of RNA editing.As an...
ProQR to Present at Two Upcoming Conferences
03 avr. 2018 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, the Netherlands, April 03, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
Vitality Biopharma Submits Orphan Drug Designation Request to FDA for Flagship THC Prodrug VITA-100
17 janv. 2018 08h00 HE
|
Vitality Biopharma, Inc
LOS ANGELES, Jan. 17, 2018 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals,...
ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa
29 nov. 2017 07h00 HE
|
ProQR Therapeutics N.V.
Key Updates ProQR’s drug candidate, QR-313 for dystrophic epidermolysis bullosa (DEB) receives orphan drug designation in the EU from the EMA.QR-313 also received U.S. ODD from the FDA in September...
ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis
25 sept. 2017 16h00 HE
|
ProQR Therapeutics N.V.
Key updates QR-010 was observed to be safe and well-tolerated across all doses in this trial with no serious adverse events related to treatment.A clinically meaningful improvement of CF respiratory...
ProQR Presents in vivo Proof of Concept Data for the Axiomer® RNA Editing Platform Technology
21 sept. 2017 07h05 HE
|
ProQR Therapeutics N.V.
Key updates ProQR presents in vivo data in a relevant disease model, establishing proof of concept for its novel and proprietary Axiomer® RNA editing platform technology.Axiomer® technology Editing...
ProQR to Present at Two Investor Conferences in September
21 sept. 2017 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, the Netherlands, Sept. 21, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that the Company will present at two investor conferences during the month of...
ProQR Receives Orphan Drug Designation from FDA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa and will Present Data at two Scientific Conferences
19 sept. 2017 07h00 HE
|
ProQR Therapeutics N.V.
Key Updates ProQR’s drug candidate QR-313 for dystrophic epidermolysis bullosa (DEB) receives orphan drug designation from the FDA, representing the fifth program in the Company’s pipeline to receive...
ProQR spins out Amylon Therapeutics as a privately-held company focused on central nervous system (CNS) therapeutics
12 sept. 2017 07h00 HE
|
ProQR Therapeutics N.V.
Key updates ProQR spins out CNS-focused company, Amylon Therapeutics, with seed funding from a group of institutional and private investors.As part of the transaction, ProQR has granted an exclusive...
ProQR’s Drug Candidate QRX-421 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA
05 sept. 2017 07h00 HE
|
ProQR Therapeutics N.V.
Key Updates ProQR’s drug candidate QRX-421 for Usher syndrome receives orphan drug designation from the FDA and EMA, representing the third candidate in the company’s ophthalmology pipeline and the...